- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.09. | Immunovia AB: Immunovia carries out a rights issue of units of approximately SEK 63 million | 150 | GlobeNewswire (Europe) | NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA... ► Artikel lesen | |
| 06.08. | Immunovia AB Q2 Loss Narrows | 1 | RTTNews | ||
| 06.08. | Immunovia AB: Immunovia Publishes Interim Report for April-June 2026 | 247 | GlobeNewswire (Europe) | Highlights April-June 2026Net sales and operating results for Q2 2026 in line with expectations: Net sales of 381 KSEK (90) for the period were comprised primarily of revenue from PancreaSure tests... ► Artikel lesen | |
| 13.05. | Immunovia AB: Bulletin From The Annual General Meeting On 13 May 2026 In Immunovia AB (publ) | 304 | GlobeNewswire (Europe) | Today, on 13 May 2026, the annual general meeting of Immunovia AB (publ) was held. A summary of the adopted resolutions follows below.
Resolution on the adoption of the accounts and allocation of resultThe... ► Artikel lesen | |
| 07.05. | Immunovia AB: Immunovia Publishes Interim Report for January-March 2026 | 417 | GlobeNewswire (Europe) | Highlights January-March 2026Net sales and operating results for Q1 2026 in line with expectations: Net sales of 374 KSEK (139) for the period included royalties and revenues from PancreaSure tests.... ► Artikel lesen | |
| 24.02. | Immunovia AB: Immunovia Publishes Full Year Report for 2025 | 704 | GlobeNewswire (Europe) | Highlights October-December 2025Net sales and operating results for Q4 2025 in line with expectations: Net sales of 354 KSEK for the period (455) largely reflected royalty revenue. Operating loss was... ► Artikel lesen | |
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| 20.01. | Immunovia AB: The Board of Directors of Immunovia withdraws proposal for reverse share split and cancels Extraordinary General Meeting | 233 | GlobeNewswire (Europe) | Following discussions with major shareholders, the Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has decided to withdraw the proposal for a reverse share split and the Extraordinary... ► Artikel lesen | |
| 19.01. | Immunovia AB: Immunovia receives state regulatory approval for PancreaSure in California and initiates commercial rollout | 346 | GlobeNewswire (Europe) | Immunovia AB (IMMNOV: Nasdaq Stockholm), a pancreatic cancer diagnostics company, today announced that it has received regulatory approval for its PancreaSure test in California, US, enabling commercial... ► Artikel lesen | |
| 17.12.25 | Immunovia AB: The Board of Directors of Immunovia proposes a reverse share split | 866 | GlobeNewswire (Europe) | The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") proposes that an Extraordinary General Meeting on 22 January 2026 resolves to carry out a reverse share split, in the ratio... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia receives final Medicare payment rate for PancreaSure test | 453 | GlobeNewswire (Europe) | LUND, Sweden - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a national payment... ► Artikel lesen | |
| 26.11.25 | Immunovia AB: Immunovia Publishes Interim Report for July-September 2025 | 478 | GlobeNewswire (Europe) | Highlights July-September 2025Net sales and operating loss for Q3 2025 in line with expectations: Net sales of 101 KSEK for the period (235) largely reflected royalty revenue. Operating loss was 25.5... ► Artikel lesen |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HIMS & HERS HEALTH | 25,400 | +1,52 % | Truist reiterates Hold on Hims and Hers stock, $32 target | ||
| BECTON DICKINSON | 162,00 | -0,55 % | BD (Becton, Dickinson and Company): BD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial Results | Data through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing... ► Artikel lesen | |
| RYMAN HEALTHCARE | 0,740 | +2,64 % | XFRA RH7: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| WELLBEING DIGITAL SCIENCES | 0,007 | -100,00 % | KGK Science Receives Growth Investment Led By Maxim Partners | ||
| NIAGEN BIOSCIENCE | 2,120 | -2,75 % | Canaccord reiterates Niagen stock rating on healthy aging strategy | ||
| SIENNA SENIOR LIVING | 12,300 | 0,00 % | Sienna Senior Living Inc: Sienna Senior to acquire Brighton retirement residence | ||
| MICROPORT SCIENTIFIC | 0,665 | -100,00 % | XFRA MSK: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMICRP.SCIEN.REGS... ► Artikel lesen | |
| EXTENDICARE | 17,100 | 0,00 % | Extendicare Inc.: Extendicare Announces Timing of 2026 Third Quarter Results and Conference Call | Markham, Ontario--(Newsfile Corp. - October 5, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") announced today that it plans to release its financial results for the third quarter... ► Artikel lesen | |
| VERADIGM | 7,350 | -100,00 % | Veradigm Inc. - 8-K, Current Report | ||
| NATIONAL HEALTHCARE CORPORATION | 200,00 | 0,00 % | Tropical storm Isaias forms, NHC forecasts hurricane prior to Gulf Coast landfall | ||
| UNIPHAR | 3,810 | -1,42 % | Dividendenbekanntmachungen (09.10.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AGNC INVESTMENT CORP US00123Q1040 0,12 USD EUR ALERUS FINANCIAL CORPORATION US01446U1034 0,22 USD EUR ALTRIA GROUP INC US02209S1033 1... ► Artikel lesen | |
| HANGZHOU TIGERMED CONSULTING | 4,980 | +0,81 % | Hangzhou Tigermed Consulting Co., Ltd.: Tigermed Announces 2026 Interim Results | HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for... ► Artikel lesen | |
| AESTHETIC MEDICAL INTERNATIONAL | 0,009 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| ADAPTHEALTH | 6,065 | 0,00 % | Morning Market Movers: Ameresco, Inno Holdings, AdaptHealth, Ibotta See Big Swings | OTTAWA (dpa-AFX) - At 7:50 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 63,65 | 0,00 % | BMO Capital reiterates Outperform on BrightSpring Health stock |
IMMUNOVIA AB gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,001 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.